FEATURE
Deferiprone in Alzheimer DiseaseA Randomized Clinical Trial
Time to read: 09:18. In this phase 2 study, the investigators aimed to determine whether deferiprone (15 mg/kg BID orally) slowed cognitive decline in Alzheimer's patients, with secondary stated outcomes being the evaluation of iron levels in the brain and its safety profile.
Source: JAMA Neurology
Feature
Text
Upper gastrointestinal mucosal damage and subsequent Risk of Parkinson Disease
Time to read: 03:48mins The researchers of this study, Chant et al. propose that notable mucosal defects, including those related to H. pylori and NSAID use, could be linked to the later development of PD, though the overall impact of NSAIDs may balance its neuroprotective benefits against any associated risks
Source: JAMA Network Open
Text
